EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-july-2023
#SafetyOfMedicines https://t.co/D0EHywwIMF

🐦🔗: https://n.respublicae.eu/EMA_News/status/1677261762968662016

At its June meeting, EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.

More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-june-2023

#SafetyOfMedicines

🐦🔗: https://n.respublicae.eu/EMA_News/status/1667127819984306176

EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.

More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-march-2023

#SafetyOfMedicines

🐦🔗: https://n.respublicae.eu/EMA_News/status/1636691621998673920

At its February meeting, EMA's safety committee, the #PRAC, started a safety review of medicines containing pseudoephedrine.

#PublicHealth #SafetyOfMedicines

➡️ https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-february-2023

🐦🔗: https://n.respublicae.eu/EMA_News/status/1624037832950939650

At its January meeting, our safety committee 🔎💊, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.

#chronicillness #SafetyOfMedicines

Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023

🐦🔗: https://n.respublicae.eu/EMA_News/status/1613886224040710148

RT @EMA_News: At its January meeting, our safety committee 🔎💊, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.

#chronicillness #SafetyOfMedicines

Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023

🐦🔗: https://n.respublicae.eu/Food_EU/status/1613888043802394627

❗️Our safety committee, the PRAC, recommends the withdrawal of pholcodine #medicines against dry cough from the EU market. Read more in our highlights.
👉https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-november-1-december-2022
#pharmacovigilance #safetyofmedicines

🐦🔗: https://n.respublicae.eu/EMA_News/status/1598661917689712642

The #PRAC recommended measures to minimise risk of serious #sideeffects with Janus kinase inhibitors for chronic inflammatory disorders.
#chronicillness #SafetyOfMedicines
https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic

🐦🔗: https://nitter.eu/EMA_News/status/1585941029844582400

EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.💊

🔎 Find all safety reviews under evaluation in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-2-5-may-2022

#SafetyOfMedicines

🐦🔗: https://nitter.eu/EMA_News/status/1522542450744639489